Tech Company Inital Public Offerings
NewLink Genetics IPO
On 11/11/2011, NewLink Genetics completed its IPO
Transaction Overview
Company Name
Announced On
11/11/2011
Transaction Type
IPO
Amount
$43,400,000
Proceeds Purpose
Proceeds purposes are on file with company statements at the SEC.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
2503 South Loop Dr. 5100
Ames, IN 50010
USA
Ames, IN 50010
USA
Phone
Website
Email Address
Overview
NewLink Genetics (NASDAQ: NLNK) is an emerging biopharmaceutical company focused on discovery and development of novel, immunotherapeutic agents. Our mission is to achieve breakthrough improvements in the survival and quality-of-life of cancer patients.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Charles Link
Chief Financial Officer
Jack Henneman
Chief Medical Officer
Eugene Kennedy
President
Nicholas Vahanian
Vice President
Mario Mautino
Vice President
Gabriela Rossi
VP - Bus. Development
Brian Wiley
VP - Finance
Carl Langren
VP - Regulatory Affairs
Lisa DeLuca
Browse more venture capital transactions:
Prev: 11/11/2011: Tarsus Medical venture capital transaction
Next: 11/11/2011: Verastem venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We report on all VC transactions involving tech companies. VC investment data records on this site are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs